Abstract. Foxp3 is a nuclear transcription factor that is both a tumor suppressor factor and regulator of T-regulatory cell (Treg) function, and is a potential therapeutic target in both autoimmunity and cancer. In order to distinguish molecular pathways responsible for these separate Foxp3 functions, deletion mutants of Foxp3 proteins were transduced and analyzed for cytotoxic activity in human cancer cell lines Skov3, MDA-MB-231, MCF-7 and Jurkat. Human Foxp3 cDNA mutants were amplified and ligated to produce plasmids for direct cell transfection. Constructs were produced and confirmed by DNA sequencing. Lipofectamine 2000 was used for plasmid transfection. Foxp3 cells were then examined. The results of our experiments reveal retention of tumor suppressor function in the absence of NFAT binding and transcriptional activation required for Treg function. Our results have significant implications for the design of autoimmune and cancer therapies that target Foxp3 and Treg cells.
Introduction
Foxp3 is an X-linked nuclear transcription factor essential to the development and program of T-regulatory cells (Tregs) that protect against the development of autoimmunity (1, 2) . The tumor suppressor activity of Foxp3 was identified when it was serendipitously observed that female mice heterozygous for the mutation in the X-linked scurfin gene (homolog to human Foxp3) have high rates of mammary cancer as well as other types of cancers (3) . Additional studies confirmed a relationship between mutations of Foxp3 and breast cancer in humans, and identified Foxp3-mediated repression of HER-2/ ErbB2 and SKP2 oncogenes as a potential mechanism for the tumor suppressor effect (3, 4) . Although Tregs suppress the development of autoimmunity, they are thought to be permissive for the development of cancer (5, 6) . Thus, Foxp3 has dual but opposing roles with respect to autoimmunity and cancer. Tregs and Foxp3 have become significant therapeutic targets in autoimmunity and cancer. Defining Foxp3 pathways responsible for its divergent functions should be helpful in the design of therapies that specifically target Foxp3. Development of the Treg function requires transcriptional activation and binding of Foxp3 to the transcription factor, NFAT (7) . In this study, Foxp3 was found to exhibit tumor suppressor activity independent of transcriptional activation and binding NFAT.
Materials and methods
Cell lines. Human cancer cell lines Skov3 (ovarian), MDA-MB-231 (breast), MCF-7 (breast) and Jurkat (T cells) were obtained from the American Type Tissue Collection (Rockville, MD, USA).
Antibodies. The antibodies used included mouse monoclonal IgG1 to human Foxp3 (sc-56680) and mouse anti-goat IgG-HRP (sc-2354) (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Plasmid constructs. Human Foxp3 cDNA was amplified by PCR from plasmid 13250 (Addgene, Cambridge, MA, USA) and ligated into pIRES2-ZsGreen1 (Clontech, Mountain View, CA, USA) to produce the plasmid pIRES2-ZsGreen1-Foxp3, pIRES2-ZsGreen1-Foxp3C (C-terminal deletion of residues 328-431) and pIRES2-ZsGreen1-Foxp3N (N-terminal deletion of residues 1-196) for direct transfection into cancer cells (Fig. 1A) . Molecular fusions of mAb 3E10 Fv were also generated as pPicZA-Fv-Foxp3, pPicZA-Fv-Foxp3-WWRR (mutations T359W, N361W, E399 and E401R of Foxp3), pPicZA-Fv-Foxp3C (C-terminal deletion of residues 328-431) and pPicZA-Fv-Foxp3N (N-terminal deletion of residues 1-196) (Fig. 1A) . Recombinant Foxp3 mutants were constructed using a QuikChange II site-directed mutagenesis Statistical analysis. A p-value was determined by a twotailed Student's t-test for non-paired samples assuming equal variances.
Results
Recombinant Fv-Foxp3 proteins. To determine whether Foxp3-mediated cytotoxicity requires NFAT, we produced and purified Foxp3 constructs shown to eliminate NFAT binding. In their study, Wu et al previously showed that the combination of selected mutations of Foxp3 C-terminal forkhead domain (FKH), T359W, N361W, E399 and E401R (WWRR) prevented NFAT binding (7). We produced Foxp3, Foxp3 WWRR mutant, and Foxp3 with C-terminal deletion of the entire FKH (∆ aa 328-431) as molecular fusion proteins with mAb 3E10 cell-penetrating Fv fragment (Fig. 1A) . The FKH is involved in DNA binding and nuclear localization, and enables transcriptional activation or repression (9) . A Western blot analyis of the purified proteins developed with antibodies to Foxp3 showed recombinant proteins of the expected sizes (Fig. 1B) .
Foxp3 cytotoxicity independent of NFAT. Cytotoxicity of Foxp3
in cancer cells was previously demonstrated by antibodymediated protein transduction (8, 10, 11) . In the present study, Fv-Foxp3 was cytotoxic in four cancer cell lines, but Foxp3 alone and the X-33 cell lysate as controls were not cytotoxic (Fig. 2) . However, Fv-Foxp3 with WWRR mutations that prevent NFAT binding was also cytotoxic in these cancer cell lines (Fig. 2) . Moreover, deletion of the entire Foxp3 FKH failed to eliminate Foxp3 cytotoxicity in cancer cells (Fig. 2) . These results were confirmed by the direct transfection of Foxp3 cDNA into Skov-3 cells. Both full-length and C-truncated Foxp3 were cytotoxic (Fig. 3) . However, an N-terminal deletion mutant of Foxp3 (Fig. 1A) completely abrogated Foxp3 cytotoxicity, indicating that the N-terminus of Foxp3 is required for Foxp3 tumor suppressor activity (Fig. 3) .
Discussion
Transcription factors form large complexes of interacting proteins that regulate gene activation pathways. Dissecting functional activation pathways is crucial to the design of therapeutic agents that target transcription factors. Tregs and Foxp3 have become significant therapeutic targets both in autoimmunity and cancer (13) . However, inhibiting Treg function to enhance tumor rejection carries risks associated with developing autoimmunity. On the other hand, enhancing Treg function to control autoimmunity may predispose to the development of cancer. More studies are therefore required to better define the divergent signaling pathways of Foxp3, thereby aiding in the design of target-specific therapies. 
A B
We have investigated the use of a cell-penetrating antibody, mAb 3E10, and its Fv fragment as an intracellular and intranuclear delivery vehicle for the delivery of transcription factor proteins, such as p53 and Foxp3 (8, 12) . The up-regulation of Foxp3 has been shown to be cytotoxic in cancer cells in vitro and in vivo (3, 8) . However, it is of concern that up-regulating Foxp3 may enhance Treg function in vivo, thereby abrogating its clinical effectiveness as a tumor suppressor in vivo. The results of our study show that Foxp3 cytotoxicity can be separated from its effect on Treg cell function by eliminating NFAT binding. Although the repressor and FKHs of Foxp3 are critical for its Treg function (14) , our study shows that cytotoxic activity is preserved in the absence of the FKH. Previous studies identified HER-2 and SKP2 oncogenes as potential targets suppressed by Foxp3 (3, 4) . Our unexpected finding that the N-terminal, but not the C-terminal, deleted Foxp3 results in loss of cytotoxicity indicates that there may be additional mechanisms for Foxp3 cytotoxicity independent of the FKH. This is not unprecedented, as the p53 tumor suppressor has been shown to mediate apoptosis by both transcription-dependent and -independent pathways (15, 16) . In our study, the role of Foxp3 N-terminus in cellular cytotoxicity may be related to its potential binding to a number of auxiliary transcription factors or chromatin-modifying proteins (17) . Further studies are required to define the role of N-terminal Foxp3 in cell toxicity. However, our finding that the Treg and tumor suppressor functions of Foxp3 are mediated through separate signaling pathways enables us to develop methods for the up-regulation of Foxp3-induced cancer cell cytotoxicity without enhancing Treg function.
